| Today’s Big NewsFeb 26, 2024 |
| By Max Bayer Johnson & Johnson is closing a nearly 200,000 square-foot R&D outpost in Brisbane, California, less than 18 months after it opened, according to multiple sources familiar with the decision. |
|
|
|
By Max Bayer While there wasn't another $3 billion private financing in 2023, it doesn't mean there wasn't plenty of money flowing. |
By Annalee Armstrong Gilead placed its “best and final” offer to buy CymaBay on January 30: $32.50 per share in cash. But the biotech’s board wanted exactly 50 cents more. |
Sponsored by The Dedham Group The influence of oncology pathways is growing. Here are the challenges and opportunities for biopharma companies in the clinical pathways landscape. |
|
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Sign Up Today! +(1)+(1).png)
|
|
By Nick Paul Taylor Boehringer Ingelheim has connected with a swing at metabolic dysfunction-associated steatohepatitis (MASH), linking its Zealand Pharma-partnered candidate to improvements in disease activity and liver scarring in a phase 2 trial. |
Sponsored by Sengenics Revolutionizing Cancer Detection: The Power of Autoantibodies |
By James Waldron GSK may have pushed back plans to secure approval for gepotidacin as the first new urinary tract infection treatment in 20 years, but fresh phase 3 results have lined up the antibiotic for a separate filing to treat gonorrhea. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
By James Waldron While Sanofi’s plans to use its blockbuster Dupixent to take on Xolair’s domination of the chronic spontaneous urticaria market were derailed by an FDA rejection last year, the French drugmaker has posted phase 2 data suggesting a BTK inhibitor may also have a shot at the crown. |
By James Waldron Following a year that saw a third of staff laid off and a sliding share price, NGM Bio has decided to go private as part of a $135 million buyout by VC firm The Column Group. |
By Helen Floersh Jasper Therapeutics’ monoclonal antibody briquilimab is effective at preventing mast-cell induced anaphylaxis and asthma in mice, new data suggest. |
By Fraiser Kansteiner Teva and Alvotech have braved a long and winding road on the quest to win approval for their biosimilar to AbbVie’s Humira. Now, after multiple manufacturing setbacks, the partners have finally scored their inaugural regulatory nod in the U.S. |
By Conor Hale The MIRA system is small enough to fit in a standard surgical tray, weighing only two pounds. With a camera and two robotic arms, it is designed to be placed entirely inside the patient’s abdomen and to conduct its work through a single cut in the navel. |
By Angus Liu The chilling wind of the biotech winter has apparently spared BeiGene. While layoffs have been commonplace in the industry, BeiGene employed 1,400 more people at the beginning of 2024 than it did a year ago. |
By Paige Minemyer LOS ANGELES — Simple HealthKit is launching a new kidney care program that aims to support health plans in driving better outcomes. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
